Aspira Women's Health Q3 revenue flat at $2.3M; gross margin expands to 64.1%

Aspira Women's Health Inc.

2025-Q3 EPS reported -$0.30 revenue$311,000

Nine-month gross profit $4.5M (+12.2% YoY); margin 64.1% vs 58.4%.
Operating expenses down 34% to $11.1M; cash burn reduced 54.5% to $5.0M.
Average unit price per test +7% YoY; sales per FTE up 167% in Q3.
Shift to profitable revenue; OvaSuite adopted by large IDN for O-RADS 4 patients.
Progress on ENDOinform endometriosis diagnostic; milestones toward commercial readiness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.